Hao Zhao

机构：Central South University, Peking University, Peking University People's Hospital, Zigong First People's Hospital, Second Xiangya Hospital of Central South University · ORCID：0000-0002-2428-7179

发表论文 63 篇 · 总被引 2010 次 · h-index 25

代表论文

• PRDM16 Regulating Adipocyte Transformation and Thermogenesis: A Promising Therapeutic Target for Obesity and Diabetes (2022 · Frontiers in Pharmacology · 被引 75)
• β-Hydroxybutyrate against Cisplatin-Induced acute kidney injury via inhibiting NLRP3 inflammasome and oxidative stress (2022 · International Immunopharmacology · 被引 53)
• Fibroblast growth factor 21 in metabolic syndrome (2023 · Frontiers in Endocrinology · 被引 33)
• Myostatin: a potential therapeutic target for metabolic syndrome (2023 · Frontiers in Endocrinology · 被引 30)
• PACS-2 deficiency aggravates tubular injury in diabetic kidney disease by inhibiting ER-phagy (2023 · Cell Death and Disease · 被引 27)
• Quercetin inhibits the NOX2/ROS-mediated NF-κB/TXNIP signaling pathway to ameliorate pyroptosis of cardiomyocytes to relieve sepsis-induced cardiomyopathy (2023 · Toxicology and Applied Pharmacology · 被引 26)